Dolinnov selected as a France 2030 laureate

Dolinnov has been selected as a France 2030 laureate. The support will accelerate the preclinical development of its lead candidate.

Three takeaways from the Non-Opioid Pain Therapeutics Summit 2026

Targeted therapies acting on the DRG, mechanism over molecule, and translation to humans as the real bottleneck: what our CEO took away from the Non-Opioid Pain Therapeutics Summit in Boston.

Dolinnov wins an i-Lab 2025 Grand Prize

Dolinnov is one of nine Grand Prize winners of i-Lab 2025, France’s national competition for deeptech start-ups, out of 473 applicants.

Dolinnov raises €1.6 million to advance its non-opioid pain programme

Dolinnov has raised €1.6 million from business angels and family offices to take its lead candidate into toxicology studies, a key step of preclinical development.

The science behind Dolinnov: an antisense approach for long-lasting pain relief

In 2023, the team showed that an antisense oligonucleotide targeting FXYD2 almost completely relieves chronic pain in rats, for up to 10 days after a single injection. This is the work Dolinnov was founded on.

The science behind Dolinnov: FXYD2 is needed for neuropathic pain to persist

In 2016, the Montpellier team showed that removing or reducing FXYD2 relieves neuropathic pain in rodents, and that FXYD2 is also present in human sensory neurons.

The science behind Dolinnov: finding FXYD2 in pain-sensing neurons

In 2012, researchers at the Montpellier Institute of Neurosciences showed that FXYD2 is present in specific pain-sensing neurons. This is where Dolinnov's story starts.